Singapore markets close in 2 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.44-0.43 (-3.62%)
At close: 04:00PM EST
11.45 +0.01 (+0.09%)
After hours: 07:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.06B
Enterprise value 2.03B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)17.84
Price/book (mrq)56.59
Enterprise value/revenue 17.78
Enterprise value/EBITDA -11.27

Trading information

Stock price history

Beta (5Y monthly) 2.49
52-week change 358.45%
S&P500 52-week change 322.93%
52-week high 318.48
52-week low 36.46
50-day moving average 313.57
200-day moving average 313.98

Share statistics

Avg vol (3-month) 32.76M
Avg vol (10-day) 32.91M
Shares outstanding 5179.94M
Implied shares outstanding 6N/A
Float 8165.69M
% held by insiders 10.91%
% held by institutions 158.43%
Shares short (14 Nov 2021) 422.55M
Short ratio (14 Nov 2021) 47.36
Short % of float (14 Nov 2021) 414.08%
Short % of shares outstanding (14 Nov 2021) 412.53%
Shares short (prior month 14 Oct 2021) 418.97M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin -198.88%
Operating margin (ttm)-160.46%

Management effectiveness

Return on assets (ttm)-51.75%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)114.03M
Revenue per share (ttm)0.64
Quarterly revenue growth (yoy)571.80%
Gross profit (ttm)-106.83M
EBITDA -182.19M
Net income avi to common (ttm)-226.78M
Diluted EPS (ttm)-1.27
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)199.6M
Total cash per share (mrq)1.11
Total debt (mrq)310.65M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.89
Book value per share (mrq)-0.82

Cash flow statement

Operating cash flow (ttm)-154.34M
Levered free cash flow (ttm)-103.06M